Loading...
•
Sep 30, 2020
Arrowhead Pharmaceuticals Q4 2020 Earnings Report
Arrowhead Pharmaceuticals reported fiscal year end results.
Key Takeaways
Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2020. The company earned two $20 million milestone payments from Amgen and signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT.
Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890.
Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis.
Initiated a Phase 1b study of ARO-HIF2, the company’s first tumor targeted investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma.
Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, which includes $300 million upfront.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Positive Outlook
- Broad portfolio of RNA chemistries
- Efficient modes of delivery
- Therapies trigger the RNA interference mechanism
- Rapid knockdown of target genes
- Durable knockdown of target genes
Challenges Ahead
- Safety and efficacy of product candidates
- Duration and impact of regulatory delays in clinical programs
- Ability to finance operations
- Likelihood and timing of the receipt of future milestone and licensing fees
- Future success of scientific studies